This invention relates to the B2-adrenoceptor agonist Olodaterol or a pharmaceutically acceptable salt thereof,

##STR00001##

for use in a method of treatment of cough from various origins.

This invention relates to the B2-adrenoceptor agonist Olodaterol or a pharmaceutically acceptable salt thereof,

##STR00001##

for use in a method of treatment of cough from various origins.

This invention relates to the B2-adrenoceptor agonist Olodaterol or a pharmaceutically acceptable salt thereof,

##STR00001##

for use in a method of treatment of cough from various origins.

The therapeutic use of azasetron or an analogue thereof for treating and/or preventing a lesion in the central auditory nervous system (CANS) in an individual. The treatment of lesions in the CANS with azasetron also prevents, inhibits, and/or reduces the loss of the central auditory neuron cells in the brainstem.

The therapeutic use of azasetron or an analogue thereof for treating and/or preventing a lesion in the central auditory nervous system (CANS) in an individual. The treatment of lesions in the CANS with azasetron also prevents, inhibits, and/or reduces the loss of the central auditory neuron cells in the brainstem.

The present invention relates to inhibitors of IRAK4 of Formula I and provides compositions comprising such inhibutors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases.

The present invention relates to inhibitors of IRAK4 of Formula I and provides compositions comprising such inhibutors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases.

The present invention relates to the field of antimicrobial agents. In particular, the present invention relates to the use of aerosolized fluoroquinolones formulated with divalent or trivalent cations and having improved pulmonary availability for the treatment and management of bacterial infections of the lung and upper respiratory tract.

The present invention relates to the field of antimicrobial agents. In particular, the present invention relates to the use of aerosolized fluoroquinolones formulated with divalent or trivalent cations and having improved pulmonary availability for the treatment and management of bacterial infections of the lung and upper respiratory tract.

Disclosed herein are compositions and methods for treating ocular diseases, inter alia, diabetic macular edema, age-related macular degeneration (wet form), choroidal neovascularization, diabetic retinopathy, retinal vein occlusion (central or branch), ocular trauma, surgery induced edema, surgery induced neovascularization, cystoid macular edema, ocular ischemia, uveitis, and the like. These diseases or conditions are characterized by changes in the ocular vasculature whether progressive or non-progressive, whether a result of an acute disease or condition, or a chronic disease or condition.